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Background: Breast cancer patients’ quality of life (QoL) after surgery has been reported to
improve signiﬁcantly over time. Little is known about QoL recovery after sentinel lymph node
biopsy (SLNB) in comparison to axillary lymph node dissection (ALND).
Methods: 175 of 195 stage I/II breast cancer patients completed the EORTC QLQ-C30: one
day before surgery (T0) and after 6 (T1), 26 (T2), 52 (T3) and 104 (T4) weeks. Of these, 54
patients underwent SLNB, 56 SLNB+ALND and 65 ALND. General linear models and
paired T-tests between T0–T4 and T1–T4 were computed. Complications, radiotherapy and
systemic therapy were added to the model.
Results: Signiﬁcant time effects were found on physical, role and emotional functioning.
Physical and role functioning decreased between T0 and T1. At T4, SLNB patients’ func-
tioning had increased to their T0 level; ALND (+/– SLNB) patients’ functioning had in-
creased, but had not improved to T0 level. Emotional functioning increased linearly between
T0 and T4. At T4, emotional functioning was significantly higher in all groups as compared
with T0. No significant group or interaction (time 9 group) effects were found. Complications
and chemotherapy had a significant negative effect on role, emotional and cognitive func-
tioning. Complications had a significant effect on social functioning also. Effect sizes varied
between 0.00 and 0.06.
Conclusion: Two years post surgery, breast cancer patients’ QoL is comparable to that
shortly before surgery. Women rated their emotional functioning as even better. SLNB is not
associated with a better QoL than ALND. However, undergoing systemic therapy and/or
experiencing complications affects QoL negatively.
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One in eight women will be confronted with breast
cancer during their life.
1 Breast cancer is the most
common malignancy in women in Western countries.
At present, the incidence of breast cancer in Europe is
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253394.3 per 100,000. With a mortality of 26.0 per
100,000, breast cancer is the most frequent cause of
death in women.
2 However, due to breast cancer
screening and new adjuvant systemic and/or hormone
therapies survival after breast cancer has improved by
7–11% over the past few years.
3–5 Consequently, the
group of breast cancer survivors is gradually
increasing, making it increasingly important to gain
insight into their quality of life.
In general, the quality of life of breast cancer sur-
vivors is reported to be good and comparable with
that of the normal population.
6–15 However, 20–30%
of breast cancer survivors continue to have problems
adjusting or experience a decreased quality of life.
16 It
is therefore essential to identify risk factors for poorer
functioning.
As far as treatment characteristics are concerned, it
has been reported that women who underwent a
mastectomy
17 and/or (adjuvant) systemic therapy
had a lower quality of life than women who did not
receive these therapies.
6,18–21 However, other research
groups did not ﬁnd any difference in quality of life
between these groups.
13,22 In addition, adjuvant
radiotherapy, particularly to the axilla, was found to
be related to functional problems in the arm and
shoulder.
23
In the 1990s, axillary lymph node dissection
(ALND) was replaced by sentinel lymph node biopsy
(SLNB) in breast cancer patients with a clinically and
ultrasound-negative axilla.
24,25 With the aid of
SLNB, it is possible to identify positive axillary
lymph nodes in a minimally invasive manner. Now-
adays, SLNB is a proven safe surgical method that
causes less morbidity than ALND.
26–29 In about one-
third to three-quarters of breast cancer patients,
SLNB prevents unnecessary staging dissection of the
axillary lymph nodes.
30–36
Several studies compared quality of life between
patients who underwent ALND and women who
underwent SLNB.
37–43 These studies showed that the
SLNB women experienced a comparable or better
quality of life than the ALND patients. However,
these studies had limitations, such as the use of
nonvalidated questionnaires, only one postoperative
measurement was performed, lack of clarity about
the stage of breast cancer in the study population, or
obscure information about the level of axillary lymph
node dissection. Four of these studies obtained lon-
gitudinal data on quality of life and had a prospective
design.
39,41–43 The limitations in these studies were
small population size,
41 or that groups were treated
according to the intention-to-treat principle, which
implies that the SLNB group also contained SLNB-
positive patients who underwent secondary ALND or
radiotherapy to the axilla.
39,42
The aim of the present study was to measure the
course of quality of life over a period of 2 years in
women with stage I or II breast cancer who under-
went SLNB, or SLNB followed by ALND
(SLNB+ALND), or ALND. It was assumed that (1)
quality of life after treatment for breast cancer would
improve over the course of time and (2) that there
would be fewer limitations in quality of life postop-
eratively after SLNB than after SLNB+ALND or
ALND. This study formes part of a larger study on
functional shoulder complaints after breast cancer
treatment.
44
METHODS
Patients
Over a 2-year period, all the women suspected of
having stage I or II breast cancer at the University
Medical Centre Groningen (UMCG) and the Martini
Hospital Groningen (MZ) were informed by the
nurse practitioner about and invited to participate in
a prospective study on quality of life following breast
cancer treatment. Exclusion criteria were distant
metastases and pre-existing shoulder complaints that
had been treated surgically, with medication or
physiotherapy. All the participants gave written in-
formed consent.
The patients ﬁlled in the ﬁrst questionnaire at the
hospital on the day before surgery (T0). Postopera-
tive questionnaires were sent to the patients 2 weeks
before each follow-up appointment, at 6 weeks (T1),
6 months (T2), 1 year (T3) and 2 years (T4). Ques-
tionnaires were ﬁlled in at home and returned to us in
a stamped addressed envelope, or brought along to
the outpatient check-up. The study was approved by
the Medical Ethics Committees (METCs) at the two
hospitals.
Treatment
The breast cancer patients underwent SLNB,
SLNB+ALND, or ALND. SNLB was conducted as
described previously.
45 When lymph node metastases
were found in the SLNB, level I–II ALND was per-
formed within 2 weeks. Surgical treatment consisted
of breast-conserving treatment or mastectomy. All
the women who underwent breast-conserving treat-
ment received postoperative radiotherapy to the
breast. Adjuvant systemic chemotherapy, hormonal
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given according to the national guidelines.
46
Questionnaires
Quality of life was measured using the EORTC-
QLQ C-30, developed by the European Organisation
in Research and Treatment of Cancer (EORTC)
study group. It is a frequently used (nationally and
internationally), validated, 30-question cancer-spe-
ciﬁc health-related questionnaire.
47 In this study, we
analysed the global quality of life score and the ﬁve
functional scales (physical, role, cognitive, emotional
and social). Each item has four answer categories: 1
= not at all, 2 = a little, 3 = rather a lot, 4 = very
much. Scores were transformed into a scale from 0 to
100 according to the manual, on which a higher
global quality-of-life score and higher functional
scores corresponded with better quality of life.
48
Statistical Analysis
Descriptive analyses were used to evaluate the study
groups. v
2 and T-tests were used to compare the
women who underwent SLNB to the other two groups
(SLNB+ALND and ALND) at T0. A general linear
model (GLM) procedure analysed longitudinal time,
group (SLNB, SLNB+ALND and ALND) and
interaction (time 9 group) eﬀects on the EORTC-
QLQ-C30subscales.Thelevelofclinicalrelevancewas
calculatedusingtheeﬀectsize,inwhichaneﬀectsizeof
0.20–0.49 reflected a small clinically relevant differ-
ence, an effect size of between 0.50–0.80 reflected a
moderate clinically relevant difference and >0.80
reflected a large clinically relevant difference.
49 To
evaluatewhetherrecoveryoccurredand/orreturnedto
the preoperative level (T0–T4) and whether postoper-
ative recovery was significant (T1–T4), paired T-tests
were used. A diﬀerence of 5–10 points on the quality-
of-life subscale of the EORTC-QLQ-C30 meant a
small clinically relevant difference, a difference of 10–
20 points meant a moderate clinically relevant differ-
ence and a difference of >20 points meant a large
clinically relevant difference.
50 All the statistical pro-
cedures were carried out with SPSS 14. Differences
were signiﬁcant at a p value of 0.05 or smaller.
RESULTS
Only six patients decided not to participate in the
study before their operation. A total of 203 patients
ﬁlled in the preoperative assessment. The surgical
ﬁndings in eight patients showed that they did not
meet the inclusion criteria: three patients had a be-
nign tumour, two patients had ductal carcinoma in
situ (DCIS), two patients had a stage 4 tumour and in
one patient the primary tumour could not be identi-
ﬁed. Consequently, 195 out of 201 eligible patients
(response rate 97%) were included in the study. It
was found that three patients had not fully completed
the preoperative questionnaire. At T1, 6 weeks after
surgery, 190 (97%) patients returned the question-
naire; at T2, 6 months after surgery, 186 patients
returned the questionnaire; at T3, 1 year after sur-
gery, 181 (93%) returned the questionnaire; at T4, 2
years after surgery, 175 (90%) returned the ques-
tionnaire. Reasons why the 20 patients (7 SLNB, 3
SLNB+ALND, 10 ALND) dropped out were: seven
had died from the disease (1 SLNB, 3
SLNB+ALND, 3 ALND), one SLNB patient was
found to have distant metastases at T4, one ALND
patient was excluded because of breast reconstruc-
tion, four patients had missing values (1 SLNB, 3
ALND) and seven patients dropped out because of
lack of interest (4 SLNB, 3 ALND) (Fig. 1).
In the remaining group of 175 patients, 110 had
undergone SLNB (63%). The biopsy had been posi-
tive in 56 patients (51%) and followed by ALND
(Fig. 1). Therefore, the SLNB group was comprised
FIG. 1. Flow chart of patients.
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comprised of 56 patients (32%) and the ALND group
was comprised of 65 patients (37%). Patient charac-
teristics of these 175 women are shown in Table 1.
Average age at inclusion was 56 years (standard
deviation [SD] 11 years); there was no signiﬁcant
difference in age between the three groups. All
lumpectomy patients and 11 mastectomy patients
received radiotherapy. Tumour–node–metastasis
(TNM) classification, breast surgery, complications,
radiotherapy and systemic therapy differed between
the groups (p varied between <0.001 to 0.011).
Therefore, the variables complications (yes/no), sys-
temic therapy (yes/no) and radiotherapy (yes/no)
were included in the analyses. A second series of
analyses was performed in which radiotherapy was
replaced by type of surgery because of overlap be-
tween the variables radiotherapy and type of surgery.
TNM classiﬁcation determines the adjuvant treat-
ment protocol (radiotherapy and/or chemotherapy)
and was therefore not included.
Quality of Life
At T0, there were no signiﬁcant diﬀerences in the
scores on the EORTC-QLQ-C30 subscales between
the three groups.
Signiﬁcant time eﬀects were found for physical,
role and emotional functioning (Table 2 and Fig. 2).
Emotional functioning improved linearly over the
course of time; physical and role functioning de-
creased between T0 and T1, increased between T1
and T2 and then stabilised. No signiﬁcant group or
time 9 group interaction effects were found. The ef-
fect sizes of time, group and interaction effects varied
from 0.000 for the group effect in global quality of
life to 0.060 for the time effect in emotional func-
tioning (Table 2).
Complications and systemic therapy had signiﬁcant
eﬀects on role, emotional and cognitive functioning;
complications also had a signiﬁcant eﬀect on social
functioning. The women who had complications and/
or systemic therapy reported poorer functioning than
the women without complications and/or systemic
therapy. Radiotherapy did not have any signiﬁcant
eﬀect on the EORTC subscales (Table 2), nor did type
of breast surgery (data not shown). The effect sizes of
these factors varied between 0.000 and 0.061.
At T4, physical and role functioning were signiﬁ-
cantly poorer (decrease of between 5–10 points) in the
SLNB+ALND and ALND groups than at T0.
Emotional functioning at T4 was significantly better
in all three groups (increase of between 10–20 points)
than at T0. Cognitive functioning was significantly
TABLE 1. Patient characteristics
Variable SLNB(N = 54) SLNB+ALND (N = 56) ALND(N = 65) Test value P
Age, years
Mean (SD) 58.1 (11.8) 53.75 (9.9) 56.5 (11.1) F = 2.19
d 0.124
TNM classiﬁcation
a N (%) N (%) N (%) v
2 = 49.24 <0.001
e
Stage I 41 (76) 8 (14) 28 (43)
Stage II A 12 (22) 42 (75) 25 (38)
Stage II B 1 (2) 6 (11) 12 (19)
Breast surgery v
2 = 15.28 <0.001
BCT
b 37 (69) 40 (71) 26 (40)
Mastectomy 17 (31) 16 (29) 39 (60)
Complications v
2 = 9.07 0.011
f
No 49 (90) 38 (68) 47 (72)
Yes
> 4 weeks seroma 2 (4) 6 (11) 10 (16)
Inﬂammation
c 3 (6) 12 (21) 8 (12)
Radiotherapy v
2 = 10.63 0.005
g
No 17 (31) 12 (21) 32 (49)
Yes
Breast 37 (69) 39 (70) 26 (40)
Breast and axilla 0 (0) 5 (9) 7 (11)
Systemic therapy v
2 = 39.89 <0.001
h
No 40 (74) 8 (14) 29 (45)
Yes
Chemo + tamoxifen - 4 (8) 8 (14) 13 (20)
Chemo + tamoxifen + 5 (9) 21 (38) 8 (12)
Chemo - tamoxifen + 5 (9) 19 (34) 15 (23)
a TNM, tumour node metastasis;
b BCT, breast-conserving therapy;
c inﬂammation treated with antibiotics;
d one-way analysis of variance
(ANOVA);
e patients diagnosed with breast cancer stage I versus IIa and IIb;
f no complications versus complications;
g no radiotherapy
versus radiotherapy;
h no systemic therapy versus systemic therapy.
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group than at T0 (Table 3).
In the ALND group, global quality of life (increase
of between 10–20 points), emotional and cognitive
functioning (increases of between 5–10 points) were
significantly higher at T4 than at T1. In the SLNB
and ALND groups, physical functioning was signif-
icantly better (increase of between 5–10 points) at T4
than at T1. Role functioning (increase of between 10–
20 points) and social functioning (increase of less
than 5 points in the SNLB group, 5–10 points in the
SLNB+ALND group and ALND group) were sig-
nificantly better at T4 than at T1 (Table 3).
DISCUSSION
This longitudinal study evaluated the quality of life
of women with stage I or II breast cancer who were
disease free 24 months after surgery. Comparisons
were made between three groups of women who were
classiﬁed according to the treatment received: SLNB,
SLNB+ALND or ALND. It was assumed that
quality of life would improve over the course of time
and that the women who had undergone SLNB
would experience better quality of life than the wo-
men who had undergone SLNB+ALND or ALND.
Signiﬁcant changes over time were found on three
subscales of the EORTC. Patterns of change diﬀered
between the three subscales. Directly after the oper-
ation, women reported their physical and role func-
tioning to be poorer than preoperatively. These
improved over the course of time. Changes over time
were signiﬁcant, but the clinical relevance was negli-
gible. At 24 months after the operation, functioning
in the women who had undergone ALND (+/–
SLNB) was poorer than preoperatively (small clinical
difference). This contradicts an earlier study that
demonstrated that, after 18 months, the functioning
of women who had been treated with SLNB or
ALND was comparable to the preoperative level.
39
However, and in line with that study, we found that,
in the women who had undergone SLNB, functioning
at 24 months after the operation was comparable
with the preoperative situation.
Emotional functioning was at the lowest level pre-
operativelyinallthreegroupsofwomen,butgradually
improvedwithtime.Itisnotsurprisingthatthewomen
experienced high levels of psychological stress after
hearing the diagnosis of breast cancer, in view of the
life-threatening nature of the disease. All the women
who participated in this study were disease free at 24
months after surgery, which suggests that treatment
was successful. This seems to be reﬂected in their im-
proved emotional functioning. The greatest improve-
ment in emotional functioning was seen at the ﬁrst
check-up, 6 weeks after the operation. The improve-
mentinemotionalfunctioningoverthe24monthsafter
surgery was moderate in clinical terms in all three
groups. An earlier study did not ﬁnd any signiﬁcant
improvement in emotional functioning over time.
41
Overall, there were no diﬀerences in quality of life
between the women treated with SLNB,
SLNB+ALNDorALND.Thiswasinagreementwith
several other studies.
41–43 However, our results were
discordant with those of the axillary lymphatic map-
ping against nodal axillary clearance (ALMANAC)
trial, in which the women who underwent SLNB
experienced better quality of life than the women who
underwent ALND.
39 These results were striking, be-
cause the SLNB group in the ALMANAC trial was
not homogeneous. Owing to the intention-to-treat
TABLE 2. General linear model (GLM)
Variable Effect FP Effect size
gQoL Time 0.21 0.935 0.001
Group
a 0.01 0.993 0.000
Interaction
b 1.14 0.331 0.013
Complications 2.81 0.095 0.016
Radiotherapy 0.10 0.754 0.001
Systemic therapy 1.16 0.203 0.010
Physical Time 3.98 0.003 0.023
Group 0.20 0.823 0.002
Interaction 1.57 0.129 0.019
Complications 0.84 0.361 0.005
Radiotherapy 0.24 0.625 0.001
Systemic therapy 0.57 0.435 0.003
Role Time 4.26 0.002 0.025
Group 0.53 0.588 0.006
Interaction 1.04 0.408 0.012
Complications 5.85 0.017 0.033
Radiotherapy 0.09 0.762 0.001
Systemic therapy 5.45 0.021 0.031
Emotional Time 10.66 <0.001 0.060
Group 0.16 0.849 0.002
Interaction 0.50 0.857 0.006
Complications 10.87 0.001 0.061
Radiotherapy 0.77 0.383 0.005
Systemic therapy 5.00 0.027 0.029
Cognitive Time 1.35 0.284 0.008
Group 0.46 0.633 0.005
Interaction 1.29 0.245 0.015
Complications 7.38 0.007 0.042
Radiotherapy 0.04 0.850 0.000
Systemic therapy 4.97 0.027 0.029
Social Time 1.42 0.225 0.008
Group 0.30 0.741 0.004
Interaction 0.44 0.899 0.005
Complications 6.68 0.011 0.038
Radiotherapy 2.94 0.089 0.017
Systemic therapy 3.31 0.071 0.019
gQoL, global quality of life;
a group = SLNB, ALND, or
SLNB+ALND;
b interaction = effect of time 9 group.
The values are in bold since they are signiﬁcant and facilitate
reading.
QUALITY OF LIFE AFTER BREAST CANCER TREATMENT 2537
Ann. Surg. Oncol. Vol. 15, No. 9, 2008FIG. 2. EORTC-QLQ-C30 global quality of life and the ﬁve functional scales.
TABLE 3. Characteristics of the EORTC-QLQ-C30 scales at the different assessment times and paired T-tests
Variable
Paired T-test
T0 T1 T2 T3 T4 T0–T4 T1–T4
Mean SD Mean SD Mean SD Mean SD Mean SD PP
gQoL
a SLNB 77.9 20.3 77.8 17.1 78.7 19.4 81.0 19.4 80.7 19.9 0.264 0.254
SLNB+ALND 81.2 18.4 71.5 23.6 76.1 18.1 77.3 20.8 76.2 19.5 0.086 0.132
ALND 80.0 15.6 70.5 18.2 76.7 17.2 81.0 20.6 81.0 17.5 0.692 <0.001
Physical SLNB 88.8 12.3 82.0 17.0 86.9 13.5 86.7 14.1 88.1 14.2 0.669 0.002
SLNB+ALND 92.6 9.9 82.7 16.1 87.5 13.3 86.9 13.7 84.3 18.1 <0.001 0.540
ALND 92.3 10.6 79.6 15.2 84.8 14.0 86.9 12.9 86.5 13.5 0.001 <0.001
Role SLNB 92.9 18.2 80.6 22.6 87.3 19.4 92.3 16.1 92.0 14.0 0.766 <0.001
SLNB+ALND 90.7 17.0 68.4 24.3 83.9 22.9 85.1 20.7 83.6 26.1 0.024 <0.001
ALND 93.3 13.7 66.9 26.7 82.5 21.7 88.9 16.4 85.6 21.8 0.014 <0.001
Emotional SLNB 72.1 20.0 84.9 17.4 87.7 15.3 86.1 15.3 89.0 19.5 <0.001 0.069
SLNB+ALND 69.4 20.5 77.4 24.3 81.9 22.0 81.9 23.7 82.4 21.6 <0.001 0.067
ALND 70.8 18.5 81.5 18.6 84.3 18.5 86.5 17.5 89.3 12.3 <0.001 0.003
Cognitive SLNB 86.7 15.7 88.6 14.8 92.3 14.4 92.0 14.0 91.0 13.6 0.038 0.280
SLNB+ALND 88.6 14.2 82.1 17.9 85.1 19.2 82.7 19.5 85.1 17.6 0.122 0.279
ALND 85.8 16.7 79.7 22.1 85.3 18.9 85.6 20.8 88.4 19.5 0.297 <0.001
Social SLNB 94.4 10.2 89.2 18.1 93.5 13.9 95.7 9.8 94.1 13.0 0.859 0.038
SLNB+ALND 90.7 18.5 80.6 22.8 87.2 19.3 90.1 19.0 88.3 20.3 0.446 0.013
ALND 91.2 15.0 84.8 19.2 90.7 16.1 93.8 17.3 94.6 14.4 0.129 <0.001
a Global quality of life; SD, standard deviation; T0, presurgery; T1, 6 weeks post-surgery; T2, 6 months post-surgery; T3, 12 months post-
surgery; T4, 24 months post-surgery.
The values are in bold since they are signiﬁcant and facilitate reading.
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adjuvant ALND or axillary radiotherapy. Further-
more, in the ALMANAC trial, ALND was per-
formed to level III, in contrast with our level II, which
may have led to more morbidity and lower quality of
life.
Lastly, in our study, we included in our analyses
treatment-related variables that were found to diﬀer
between the groups. The women who had systemic
therapy and/or complications reported poorer quality
of life on some of the subscales than those without. It
appeared that adjustments in QoL were not so much
related to the surgical treatment (SLNB or ALND),
but to these treatment-related variables.
Neither radiotherapy nor type of breast surgery
had any signiﬁcant eﬀect on functioning according to
the reports made by the women. Earlier publications
showed an eﬀect of chemotherapy and an eﬀect of
radiotherapy.
51–53 The literature is largely in line with
our ﬁnding that there is no advantage in quality of
life of lumpectomy over mastectomy.
54
On the whole it should be noted that comparisons
with the literature were hampered by diﬀerences in
study design and measurement instruments (Table 4).
TABLE 4. Overview of results from longitudinal studies on quality of life comparing SLNB, SLNB+ALND and ALND in
breast cancer patients
Study Year Design
Assessment
times
Study groups
Measurement
instrument Results SLNB S+A
c ALND
Peintinger
et al.
41
2003 Prospective T0: pre-surgery
T1: post-surgery
T2: 9–12 months
25 31 EORTC-QLQ-C30
(functional scales
and global QoL)
At T1 SLNB patients reported
higher global QoL than at T0.
At T2, both groups reported higher
global QoL than at T0. No other
time differences were found.
No differences between groups
were found.
Purushotham
et al.
42
2005 RCT T0: post-surgery
T1: 3 months
T2: 6 months
T3: 12 months
134
a 143 SF-36 (physical
summary
score, physical
functioning,
vitality)
At T0, SLNB patients reported
higher on physical summary score,
physical functioning and vitality
than ALND patients. No differences
between groups were found at later
follow-up times.
Fleissig
et al.
39
2006 RCT T0: pre-surgery
T1: 1 months
T2: 3 months
T3: 6 months
T4: 12 months
T5: 18 months
424
b 405 FACT-B+4
total score,
TOI
SLNB patients reported better QoL
at all postoperative measurement
times and faster recovery to baseline
levels than ALND patients. Decline
in TOI was >5 points in the ALND
group at T1, T2 and T4. No
clinically relevant change in TOI
was found in the SLNB group.
Del Bianco
et al.
43
2007 Clinical
trial
T0: pre-surgery
T1: 6 months
T2: 12 months
T3: 24 months
159
a 151 SF-36 (physical
and mental
summary scores),
PGWB (total
index and anxiety)
No differences between study groups
were found in the physical and
mental summary scores. At T1,
SLNB patients reported a higher
mean PGBW score. At later
measurement times, no signiﬁcant
differences between groups were
found. At T1, T2 and T3 both
groups reported a decline in
physical summary score compared
to T0.
Kootstra
et al.
2008 Prospective T0: pre-surgery
T1: 6 weeks
T2: 6 months
T3: 12 months
T4: 24 months
54 56 65 EORTC-QLQ-C30
(functional scales
and global QoL)
Signiﬁcant time effects were found in
physical, role and emotional
functioning. No signiﬁcant effects of
treatment groups were found on any
of the scales. At T4, all patients
reported higher emotional
functioning than at T0. At T4,
ALND patients (+/– SLNB)
reported lower physical and role
functioning than at T0.
a SLNB group included women treated with SLNB+ALND;
b SLNB group included women treated with SLNB+ALND and women
treated with SLNB+ axillary radiotherapy.
c SLNB followed by ALND; RCT, randomised clinical trial; FACT-B+4, functional assessment
cancer therapy breast version 4; TOI, trial outcome index; PGWB, phychological general well-being.
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rate, the use of a validated disease-speciﬁc quality-of-
life questionnaire combined with a preoperative
assessment, multiple postoperative measurements
and a longitudinal analysis on diﬀerent domains of
quality of life. A limitation of the study is that no
a priori power analysis was performed. Although
attrition was low, the size of the groups may not have
been large enough to prevent type I or II errors.
However, the clinical relevance of all diﬀerences
found was negligible in size. It is questionable whe-
ther analyses using larger groups would reveal clini-
cally relevant diﬀerences.
CONCLUSION
Physical functioning and role functioning in
women with stage I or II breast cancer were lowest
directly after the operation, but improved with time.
Emotional functioning was lowest preoperatively, but
continued to improve postoperatively. There were no
diﬀerences in quality-of-life domains over the course
of time between the patients treated with SLNB,
SLNB+ALND or ALND. Women with complica-
tions or systemic therapy had poorer role, emotional,
cognitive and social functioning than their counter-
parts without these factors.
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